Sante Capital Fund’s Biogen BIIB Stock Holding History

Sante Capital Fund’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,771	Closed	-$1.64M	–	35
2022 Q1	$1.64M	Buy	+7,771	New	+$1.69M	1.83%	20

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sante Capital Fund's BIIB Position: Q2 2022 in Review

Sante Capital Fund sold out of Biogen (BIIB) in Q2 2022, closing a stake of 7,771 shares — an estimated $1.64M sold.

Sante Capital Fund first reported a position in BIIB in Q1 2022 and held it in 1 quarter. The position peaked at $1.64M in Q1 2022. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Sante Capital Fund reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
Sante Capital Fund sold 7,771 Biogen shares in Q2 2022, an estimated $1.64M.
Sante Capital Fund first reported a position in Biogen in Q1 2022 and held it in 1 quarter.
Sante Capital Fund's Biogen position peaked at $1.64M in Q1 2022.
927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Sante Capital Fund's 13F filing for Q2 2022, filed 27 Jul 2022.